Cargando…

Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms

Background: If the diagnosis of neuroendocrine neoplasm (NEN) increases the risk of patients to commit suicide has not been investigated so far. Identifying NEN patients at risk to commit suicide is important to increase their life quality and life expectancy. Methods and findings: Cancer cases were...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Lili, Shang, Yuru, Zechner, Dietmar, Mullins, Christina Susanne, Linnebacher, Michael, Zhang, Xianbin, Gong, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225995/
https://www.ncbi.nlm.nih.gov/pubmed/34177643
http://dx.doi.org/10.3389/fpsyt.2021.638152
_version_ 1783712188939108352
author Lu, Lili
Shang, Yuru
Zechner, Dietmar
Mullins, Christina Susanne
Linnebacher, Michael
Zhang, Xianbin
Gong, Peng
author_facet Lu, Lili
Shang, Yuru
Zechner, Dietmar
Mullins, Christina Susanne
Linnebacher, Michael
Zhang, Xianbin
Gong, Peng
author_sort Lu, Lili
collection PubMed
description Background: If the diagnosis of neuroendocrine neoplasm (NEN) increases the risk of patients to commit suicide has not been investigated so far. Identifying NEN patients at risk to commit suicide is important to increase their life quality and life expectancy. Methods and findings: Cancer cases were extracted from the Surveillance, Epidemiology, and End Results program and were divided into the NEN and the non-NEN cohorts. Subsequently, the NEN patients were randomly split into a training data set and a validation data set. Analyzing the training data set, we developed a score for assessing the risk to commit suicide for patients with NEN. In addition, we validated the score using the validation data set and evaluated, if this score could also be applied to other cancer entities by using the test data set, a non-NEN cohort. The odds ratio (OR) of suicide between NEN and non-NEN patients was determined. Moreover, the performance of a score was evaluated by the receiver operating characteristic curve and the area under the curve (AUC). Compared to non-NEN, NEN significantly increased the risk of suicide to 1.8-fold (NEN vs. non-NEN; OR, 1.832; P < 0.001). In addition, we observed that age, gender, race, marital status, tumor stage, histologic grade, surgery, and chemotherapy were associated with suicide among NEN patients; and a synthesized score based on these factors could significantly distinguish suicide individuals from non-suicide individuals in the training data set (AUC, 0.829; P < 0.001) and in the validation data set (AUC, 0.735; P < 0.001). This score also had a good performance when it was assessed by the test data set (AUC, 0.690; P < 0.001). This demonstrates that the score might also be applicable to other cancer entities. Conclusions: This population-based study suggests that NEN patients have a higher risk of suicide than non-NEN patients. In addition, this study provided a score, which can identify NEN patients at high-risk of committing suicide. Thus, this score in combination with current screening and prevention strategies for suicide may improve life quality and life expectancy of NEN patients.
format Online
Article
Text
id pubmed-8225995
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82259952021-06-26 Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms Lu, Lili Shang, Yuru Zechner, Dietmar Mullins, Christina Susanne Linnebacher, Michael Zhang, Xianbin Gong, Peng Front Psychiatry Psychiatry Background: If the diagnosis of neuroendocrine neoplasm (NEN) increases the risk of patients to commit suicide has not been investigated so far. Identifying NEN patients at risk to commit suicide is important to increase their life quality and life expectancy. Methods and findings: Cancer cases were extracted from the Surveillance, Epidemiology, and End Results program and were divided into the NEN and the non-NEN cohorts. Subsequently, the NEN patients were randomly split into a training data set and a validation data set. Analyzing the training data set, we developed a score for assessing the risk to commit suicide for patients with NEN. In addition, we validated the score using the validation data set and evaluated, if this score could also be applied to other cancer entities by using the test data set, a non-NEN cohort. The odds ratio (OR) of suicide between NEN and non-NEN patients was determined. Moreover, the performance of a score was evaluated by the receiver operating characteristic curve and the area under the curve (AUC). Compared to non-NEN, NEN significantly increased the risk of suicide to 1.8-fold (NEN vs. non-NEN; OR, 1.832; P < 0.001). In addition, we observed that age, gender, race, marital status, tumor stage, histologic grade, surgery, and chemotherapy were associated with suicide among NEN patients; and a synthesized score based on these factors could significantly distinguish suicide individuals from non-suicide individuals in the training data set (AUC, 0.829; P < 0.001) and in the validation data set (AUC, 0.735; P < 0.001). This score also had a good performance when it was assessed by the test data set (AUC, 0.690; P < 0.001). This demonstrates that the score might also be applicable to other cancer entities. Conclusions: This population-based study suggests that NEN patients have a higher risk of suicide than non-NEN patients. In addition, this study provided a score, which can identify NEN patients at high-risk of committing suicide. Thus, this score in combination with current screening and prevention strategies for suicide may improve life quality and life expectancy of NEN patients. Frontiers Media S.A. 2021-06-11 /pmc/articles/PMC8225995/ /pubmed/34177643 http://dx.doi.org/10.3389/fpsyt.2021.638152 Text en Copyright © 2021 Lu, Shang, Zechner, Mullins, Linnebacher, Zhang and Gong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Lu, Lili
Shang, Yuru
Zechner, Dietmar
Mullins, Christina Susanne
Linnebacher, Michael
Zhang, Xianbin
Gong, Peng
Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms
title Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms
title_full Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms
title_fullStr Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms
title_full_unstemmed Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms
title_short Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms
title_sort development and validation of a score for screening suicide of patients with neuroendocrine neoplasms
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225995/
https://www.ncbi.nlm.nih.gov/pubmed/34177643
http://dx.doi.org/10.3389/fpsyt.2021.638152
work_keys_str_mv AT lulili developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms
AT shangyuru developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms
AT zechnerdietmar developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms
AT mullinschristinasusanne developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms
AT linnebachermichael developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms
AT zhangxianbin developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms
AT gongpeng developmentandvalidationofascoreforscreeningsuicideofpatientswithneuroendocrineneoplasms